





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07C 227/04, 229/28, 205/51</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/39074</b> <b>(43) International Publication Date:</b> 6 July 2000 (06.07.00)
<b>(21) International Application Number:</b> PCT/HU99/00102 <b>(22) International Filing Date:</b> 23 December 1999 (23.12.99) <b>(30) Priority Data:</b> P 9803034 29 December 1998 (29.12.98) HU <b>(71) Applicant (for all designated States except US):</b> RICHTER GEDEON VEGYÉSZETI GYÁR RT. [HU/HU]; Gyömrői út 19-21, H-1103 Budapest X. (HU). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GIZUR, Tibor [HU/HU]; Avarszállás u. 30, H-1162 Budapest (HU). LENGYEL, Zoltánné [HU/HU]; Zirzen J. u. 40/c., H-1125 Budapest (HU). SZALAI, Krisztina [HU/HU]; Sarkadi út 2. VI. em. 20., H-1039 Budapest (HU). <b>(74) Common Representative:</b> RICHTER GEDEON VEGYÉSZETI GYÁR RT.; Gyömrői út 19-21, H-1103 Budapest X. (HU).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PROCESS FOR THE SYNTHESIS OF 1-(AMINOMETHYL)CYCLOHEXYL-ACETIC ACID		
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div> </div>		
<b>(57) Abstract</b>  <p>The invention relates to a new process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid of formula (I) via the new intermediate 1-(nitromethyl)cyclohexyl-acetic acid derivative of formula (II), wherein R represents hydrogen, benzyl group, diphenylmethyl group or C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy aromatic ring substituted derivatives thereof.</p>		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**Process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid**

The invention relates to a new process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid of the formula (I) via the new  
5 intermediate 1-(nitromethyl)cyclohexyl-acetic acid derivative of general formula (II), wherein R represents hydrogen, benzyl group, diphenylmethyl group or C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy aromatic ring substituted derivatives thereof.



The 1-(aminomethyl)cyclohexyl-acetic acid of formula (I), otherwise known as gabapentin is the active ingredient of the GABA antagonist drug. Several methods are known from the literature for the synthesis of  
15 this compound.

In most of the known methods an intermediate is hydrolysed with acid, and gabapentin is obtained from the so formed gabapentin hydrochloride salt by using ion exchange resin. This process is described in the German patent No. DE 2 460 891, in which the 1,1-cyclohexyldiacetic acid anhydride is converted into hydroxamic acid and  
20 the latter is transformed via Lossen degradation into the hydrochloride salt of the product. The US patent No. US 4 024 175 describes a method where the same 1,1-cyclohexyldiacetic acid anhydride is used as starting material. The anhydride is first transformed into a monomethyl ester  
25 monosalt and then a monoacid monoazide is obtained from it. The gabapentin hydrochloride is prepared from the latter via Curtius degradation.

Similarly gabapentin hydrochloride is formed in the procedure described in the European patent No. EP 414 274. According to this

invention the alkyl ester of 1-(nitromethyl)acetic acid is transformed into a 2-aza-spiro[4,5]decane-3-on derivative by catalytic hydrogenation. The gabapentin hydrochloride is obtained from the latter lactam derivative by refluxing it with hydrochloric acid and gabapentin is isolated by using ion-exchange resin.


The disadvantages of the above mentioned procedures are as follows. The gabapentin is obtained as its hydrochloride salt and gabapentin itself can be isolated only by using labour-demanding and expensive ion-exchange method. To avoid the unwanted lactam formation side-reaction requires also a labour-demanding and expensive technique. Further disadvantages of these procedures are the use of hazardous reagents, e.g. potassium cyanide, sodium azide and the expensive pressure resistant equipment.

The procedure described in the European patent No. EP 414 275 avoids the formation of the lactam compound and the gabapentin hydrochloride, and this way the use of the expensive ion-exchange method. According to this procedure cyano-cyclohexane-maleinic acid derivatives are hydrolysed with base, decarboxylated and finally the nitril group is catalytically hydrogenated. On the other hand this patent does not describe the synthesis of the cyano-cyclohexane-maleinic acid derivatives, which is a multi step, tedious process. It is important to note, that the synthesis of the maleinic acid ester is four steps starting from cyclohexanon, so the synthesis of gabapentin is altogether seven steps. The patent does not mention the purity of the obtained gabapentin either, in contrast to other patents, which describe the synthesis of gabapentin, e.g. EP 414 274.

The aim the invention is to elaborate an economical, industrially applicable process for the synthesis of gabapentin, which eliminates the disadvantages of the above mentioned procedures and makes possible the simple synthesis of the very pure final product of formula (I) in fewer steps and in good yield.

The synthesis of gabapentin according to the process of the invention is as follows

- a) the alkyl ester of cyclohexylidene-acetic acid of general formula (VI) — wherein  $R_2$  represents  $C_1$ - $C_4$  alkyl group — is transformed into the alkyl ester of 1-(nitromethyl)cyclohexyl-acetic acid of general formula (V) —  
 5        wherein the meaning of  $R_2$  is as defined above — with nitromethane in the presence of a base, the latter is hydrolysed with aqueous methanolic solution of potassium hydroxide and the obtained 1-(nitromethyl)cyclohexyl-acetic acid of formula (IIa) is hydrogenated in a  
 10        solvent in the presence of a catalyst to yield the desired product of formula (I), or




- b) the alkyl ester of cyclohexylidene-acetic acid of general formula (VI) — wherein the meaning of  $R_2$  is as defined above — is hydrolysed with aqueous methanolic solution of potassium hydroxide and the obtained cyclohexylidene-acetic acid of formula (IV) is reacted with a reagent of  
 20        formula  $R_1$ -X — wherein  $R_1$  represents benzyl group, diphenylmethyl group or in given case  $C_1$ - $C_4$  alkyl or alkoxy aromatic ring substituted derivatives thereof — to give the appropriate cyclohexylidene acid derivative of general formula (III) — wherein the meaning of  $R_1$  is as  
 25        defined above — and this intermediar is transformed into 1-(nitromethyl)cyclohexyl-acetic acid derivative of general formula (IIb) —

wherein the meaning of  $R_1$  is as defined above — with nitromethane and the latter is hydrogenated in a solvent in the presence of a catalyst.



5



The process of the invention is illustrated on Scheme 1.

The invention based on the observation, that the reduction of the new compounds of general formula (II) at atmospheric pressure yields directly the pure desired final product.

Surprisingly it was found, that using the compounds of general formula (II) as starting materials in the reduction step the lactam compound is not formed, but the very pure gabapentin is obtained directly. This was not anticipated in the knowledge of previous procedures, as the ability of lactam formation of this type of compounds is known from the literature (e.g. EP 414 274).

The alkyl ester of cyclohexylideneacetic acid of general formula (VI) used as starting material can be prepared according to the literature via the reaction of cyclohexanone and the appropriate ester of diethylphosphono-acetic acid.

In the last hydrogenation step any catalysts can be used, which are generally applicable in hydrogenation reactions, rare metal catalysts, e.g. rhodium or palladium, Raney nickel or cobalt catalysts, in given case on a carrier e.g. on carbon, preferably palladium on activated carbon, more preferably 10% of the compound to be reduced.

The hydrogenation is carried out in an inert organic solvent, preferably in a  $\text{C}_1\text{-C}_4$  alcohol, more preferably in methanol, at  $10\text{-}50^\circ\text{C}$ ,

under 1-20 kPa pressure, preferably at room temperature and under atmospheric pressure.

The Michael addition of the ester of cyclohexylidene-acetic acid with nitromethane is carried out in the presence of a base, preferably potassium hydroxide.

The hydrolysis of the alkyl ester group is carried out with base, preferably aqueous methanolic solution of potassium hydroxide at room temperature, then the acid is liberated with 10% aqueous potassium dihydrogenphosphate solution.

After filtration of the catalyst the product is isolated by concentration of the filtrate. The product obtained on concentration is 98-99% pure, the yield is 50-70%.

The advantages of this procedure are as follows:

- the obtained product is very pure
- the number of reaction steps is less than in the known procedures
- the lactam compound, which is very difficult to remove, is not formed
- neither special pressure resistant equipment nor expensive catalyst is needed
- the final product can be obtained without applying difficult and complicated ion-exchange technology
- no poisonous or dangerous materials are needed

## Examples

### *Example 1*

a) Synthesis of 1-(nitromethyl)cyclohexyl-acetic acid

A solution of 4.3 g (0.02 mol) of methyl 1-(nitromethyl)cyclohexyl-acetate in a mixture of 50 ml of methanol and 20 ml of 10% aqueous potassium hydroxide is stirred at room temperature for 24 h, then the methanol is distilled off in vacuo. The pH of the resulted aqueous solution is adjusted to 7 with 10% aqueous potassium dihydrogenphosphate solution. The

solution is extracted three times with 30 ml of ethyl acetate, the combined organic layers are dried over sodium sulphate and concentrated to yield 3.2 g (80%) of the title compound as oil.

5    b) Synthesis of 1-(aminomethyl)cyclohexyl-acetic acid

A solution of 2.01 g (0.01 mol) of 1-(nitromethyl)cyclohexyl-acetic acid in 50 ml of methanol is hydrogenated in the presence of 0.2 g of palladium on activated carbon at atmospheric pressure. The catalyst is filtered off and the filtrate is concentrated to 10 ml. 20 ml of tetrahydrofuran is added  
10    to the residue and the precipitated crystals were filtered off and dried to yield 1.3 g (80%) of the title compound. Mp: 164-169°C

---

*Example 2*

Synthesis of 1-(aminomethyl)cyclohexyl-acetic acid


15    A solution of 5 g (0.017 mol) of benzyl 1-(nitromethyl)cyclohexyl-acetate in 50 ml of methanol is added to a mixture of 0.5 g of prehydrogenated palladium, 10% on activated carbon in 50 ml of methanol. This mixture is hydrogenated at room temperature under atmospheric pressure until the calculated hydrogen is consumed, then the catalyst is filtered off, the  
20    filtrate is concentrated to about 15 ml and 30 ml of tetrahydrofuran is added to precipitate the title compound. Yield: 1.5 g (51%). Mp: 168°C.



**Claims:**


1. Process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid and pharmaceutically acceptable salt thereof characterised by

a) transformation of the alkyl ester of cyclohexylidene-acetic acid of formula (VI) — wherein  $R_2$  represents  $C_1$ - $C_4$  alkyl group — into the alkyl ester of 1-(nitromethyl)cyclohexyl-acetic acid of formula (V) — wherein the meaning of  $R_2$  is as defined above — with nitromethane in the presence of a base, hydrolysis with aqueous methanolic solution of potassium hydroxide and hydrogenation of the obtained 1-(nitromethyl)cyclohexyl-acetic acid of formula (IIa) in the presence of a catalyst and in given case transformation of the obtained compound into a pharmaceutically acceptable salt or



b) hydrolysis of the alkyl ester of cyclohexylidene-acetic acid of formula (VI) — wherein  $R_2$  represents  $C_1$ - $C_4$  alkyl group — into the cyclohexylidene-acetic acid of formula (IV) with aqueous methanolic solution of potassium hydroxide, reaction of the obtained acid of formula (IV) with a reagent of formula  $R_1$ -X — wherein  $R_1$  represents benzyl group, diphenylmethyl group or in given case  $C_1$ - $C_4$  alkyl or alkoxy aromatic ring substituted derivatives thereof and X represents halogen atom — to give the intermediar cyclohexylidene acid derivative of formula (III) — wherein the meaning of  $R_1$  is as defined above — transformation of this intermediar into the 1-(nitromethyl)cyclohexyl-acetic acid derivative of formula (IIb) — wherein the meaning of  $R_1$  is as defined above — and

hydrogenation of the latter in a solvent in the presence of a catalyst and in given case transformation of the obtained compound into a pharmaceutically acceptable salt.



5

2. Process b) of claim 1 characterised by using benzyl halide as reagent of formula  $R_1-X$ .

3. Process b) of claim 1 characterised by using diphenylmethyl halide as reagent of formula  $R_1-X$ .

10

4. The process of claim 1-3 characterised by carrying out the hydrogenation in an inert organic solvent.

5. The process of claim 1-3 characterised by using palladium on activated carbon as catalyst.

6. The new compounds of formula (II), wherein R represents hydrogen, benzyl, diphenylmethyl group or in given case  $C_1-C_4$  alkyl or alkoxy aromatic ring substituted derivatives thereof.

15

7. 1-(nitromethyl)cyclohexyl-acetic acid

8. benzyl 1-(nitromethyl)cyclohexyl-acetate

9. diphenylmethyl 1-(nitromethyl)cyclohexyl-acetate

20

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/HU 99/00102

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C227/04 C07C229/28 C07C205/51

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 414 274 A (GOEDECKE AG) 27 February 1991 (1991-02-27) cited in the application page 6 -page 12	1,4,5
Y	<p style="text-align: center;">---</p> <p>BRYANS J S ET AL: "Investigation into the preferred conformation of Gabapentin for interaction with its binding site on the alpha2delta subunit of a calcium channel" BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 19, 7 October 1997 (1997-10-07), pages 2481-2484, XP004136469 ISSN: 0960-894X the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1,4,5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 March 2000

Date of mailing of the international search report

29/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

PCT/HU 99/00102

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HU 99/00102

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0414274 A	27-02-1991	DE 3928182 A AT 90936 T DK 414274 T ES 2058707 T FI 103040 B HU 54623 A,B IL 95479 A JP 2846084 B JP 3118355 A US 5091567 A	28-02-1991 15-07-1993 09-08-1993 01-11-1994 15-04-1999 28-03-1991 12-09-1996 13-01-1999 20-05-1991 25-02-1992
WO 9921824 A	06-05-1999	AU 9663898 A	17-05-1999
EP 0414263 A	27-02-1991	DE 3928183 A AT 113272 T DE 59007550 D DK 414263 T ES 2063219 T HK 1003480 A IE 65291 B JP 3090053 A PT 95082 A,B	28-02-1991 15-11-1994 01-12-1994 16-01-1995 01-01-1995 30-10-1998 18-10-1995 16-04-1991 18-04-1991
EP 0432504 A	19-06-1991	AT 106861 T CA 2030107 A DE 59006037 D DK 432504 T ES 2057334 T FI 905584 A JP 3176459 A NO 177531 B PT 95894 A,B RU 2029761 C US 5095148 A US 5130455 A US 5149870 A US 5136091 A	15-06-1994 17-05-1991 14-07-1994 04-07-1994 16-10-1994 17-05-1991 31-07-1991 26-06-1995 13-09-1991 27-02-1995 10-03-1992 14-07-1992 22-09-1992 04-08-1992